View Future GrowthSoulbrain 과거 순이익 실적과거 기준 점검 1/6Soulbrain의 수입은 연평균 -13.1%의 비율로 감소해 온 반면, Chemicals 산업은 수입이 연평균 1.1% 증가했습니다. 매출은 연평균 5%의 비율로 감소해 왔습니다. Soulbrain의 자기자본이익률은 7.6%이고 순이익률은 8.6%입니다.핵심 정보-13.05%순이익 성장률-12.92%주당순이익(EPS) 성장률Chemicals 산업 성장률13.95%매출 성장률-5.03%자기자본이익률7.56%순이익률8.56%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트Reported Earnings • Mar 21Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.분석 기사 • Mar 24There May Be Some Bright Spots In Soulbrain's (KOSDAQ:357780) EarningsSoft earnings didn't appear to concern Soulbrain Co., Ltd.'s ( KOSDAQ:357780 ) shareholders over the last week. Our...Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022)Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.Reported Earnings • Mar 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea.모든 업데이트 보기Recent updatesBuy Or Sell Opportunity • May 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.8% to ₩392,000. The fair value is estimated to be ₩494,529, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 32% per annum over the same time period.Price Target Changed • May 05Price target increased by 11% to ₩428,846Up from ₩385,833, the current price target is an average from 13 analysts. New target price is 6.5% below last closing price of ₩458,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩20,528 for next year compared to ₩10,285 last year.Buy Or Sell Opportunity • Apr 30Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to ₩458,000. The fair value is estimated to be ₩573,521, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 32% per annum over the same time period.Reported Earnings • Mar 21Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩442,000, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 106% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩419,479 per share.공시 • Mar 11Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 52, geumto-ro, sujeong-gu, gyeonggi-do, seongnam South KoreaPrice Target Changed • Mar 02Price target increased by 8.9% to ₩365,571Up from ₩335,667, the current price target is an average from 14 analysts. New target price is 18% below last closing price of ₩445,500. Stock is up 140% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year.Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩407,000, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩490,528 per share.Declared Dividend • Feb 06Dividend increased to ₩2,350Dividend of ₩2,350 is 2.2% higher than last year. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.6%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but not covered by cash flows (118% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 91% over the next 2 years, which should provide support to the dividend and adequate earnings cover.분석 기사 • Feb 05Soulbrain (KOSDAQ:357780) Will Be Hoping To Turn Its Returns On Capital AroundThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...공시 • Feb 05Soulbrain Co., Ltd. announces Annual dividendSoulbrain Co., Ltd. announced Annual dividend of KRW 2350.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026.Price Target Changed • Feb 02Price target increased by 7.3% to ₩329,333Up from ₩307,063, the current price target is an average from 15 analysts. New target price is 21% below last closing price of ₩419,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year.New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.5% net profit margin).Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩339,500, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩623,091 per share.분석 기사 • Jan 08Market Participants Recognise Soulbrain Co., Ltd.'s (KOSDAQ:357780) EarningsWith a price-to-earnings (or "P/E") ratio of 33.7x Soulbrain Co., Ltd. ( KOSDAQ:357780 ) may be sending very bearish...Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩229,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years.Major Estimate Revision • Nov 15Consensus EPS estimates increase by 14%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩14,296 to ₩16,301. Revenue forecast steady at ₩922.7m. Net income forecast to grow 92% next year vs 49% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩289,643. Share price rose 3.5% to ₩268,000 over the past week.분석 기사 • Nov 07What Is Soulbrain Co., Ltd.'s (KOSDAQ:357780) Share Price Doing?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), is not the largest company out there, but it led the KOSDAQ gainers with a...분석 기사 • Oct 22Soulbrain's (KOSDAQ:357780) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...분석 기사 • Sep 19Soulbrain Co., Ltd. (KOSDAQ:357780) Stocks Shoot Up 26% But Its P/E Still Looks ReasonableDespite an already strong run, Soulbrain Co., Ltd. ( KOSDAQ:357780 ) shares have been powering on, with a gain of 26...Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩242,000, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 22% over the past three years.분석 기사 • Sep 07These 4 Measures Indicate That Soulbrain (KOSDAQ:357780) Is Using Debt Reasonably WellWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Large one-off items impacting financial results.Major Estimate Revision • Aug 19Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩18,980 to ₩16,480 per share. Revenue forecast steady at ₩938.7m. Net income forecast to grow 35% next year vs 35% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩253,308. Share price fell 2.3% to ₩229,000 over the past week.Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩248,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 9.7% over the past three years.Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩211,500, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 3.3% over the past three years.분석 기사 • Jul 12Soulbrain Co., Ltd.'s (KOSDAQ:357780) P/E Still Appears To Be ReasonableWith a median price-to-earnings (or "P/E") ratio of close to 14x in Korea, you could be forgiven for feeling...분석 기사 • May 14Is There An Opportunity With Soulbrain Co., Ltd.'s (KOSDAQ:357780) 30% Undervaluation?Key Insights Soulbrain's estimated fair value is ₩265,300 based on 2 Stage Free Cash Flow to Equity Soulbrain's...공시 • Apr 16Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for 86,009 shares, for KRW 15,000 million.Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to 86,009 shares for KRW 15,000 million worth of its shares pursuant to a trust agreement with NH Investment & Securities Co., Ltd. The shares will be repurchased at a price of KRW 174,400 per share. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until October 14, 2025. As of Aril 14, 2025, the company had 22,994 common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions.분석 기사 • Apr 15Why Soulbrain Co., Ltd. (KOSDAQ:357780) Could Be Worth WatchingSoulbrain Co., Ltd. ( KOSDAQ:357780 ), might not be a large cap stock, but it saw a double-digit share price rise of...Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩161,200, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.분석 기사 • Mar 24There May Be Some Bright Spots In Soulbrain's (KOSDAQ:357780) EarningsSoft earnings didn't appear to concern Soulbrain Co., Ltd.'s ( KOSDAQ:357780 ) shareholders over the last week. Our...Upcoming Dividend • Mar 21Upcoming dividend of ₩2,300 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.7%).Major Estimate Revision • Mar 19Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩20,044 to ₩17,886 per share. Revenue forecast steady at ₩901.4m. Net income forecast to grow 9.4% next year vs 26% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩257,385. Share price was steady at ₩204,500 over the past week.공시 • Mar 11Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 34-12, gongdan-gil, chungcheongnam-do, gongju South Korea분석 기사 • Feb 21Soulbrain (KOSDAQ:357780) Might Be Having Difficulty Using Its Capital EffectivelyIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩188,100, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩331,465 per share.분석 기사 • Jan 09Is There An Opportunity With Soulbrain Co., Ltd.'s (KOSDAQ:357780) 49% Undervaluation?Key Insights The projected fair value for Soulbrain is ₩351,381 based on 2 Stage Free Cash Flow to Equity Soulbrain is...Upcoming Dividend • Dec 20Upcoming dividend of ₩2,000 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (2.2%).Board Change • Dec 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.분석 기사 • Dec 02Unpleasant Surprises Could Be In Store For Soulbrain Co., Ltd.'s (KOSDAQ:357780) SharesWith a median price-to-earnings (or "P/E") ratio of close to 11x in Korea, you could be forgiven for feeling...Price Target Changed • Nov 16Price target decreased by 13% to ₩317,692Down from ₩363,167, the current price target is an average from 13 analysts. New target price is 66% above last closing price of ₩191,300. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩20,134 for next year compared to ₩16,832 last year.분석 기사 • Nov 07At ₩204,500, Is Soulbrain Co., Ltd. (KOSDAQ:357780) Worth Looking At Closely?While Soulbrain Co., Ltd. ( KOSDAQ:357780 ) might not have the largest market cap around , it saw significant share...분석 기사 • Oct 09Capital Allocation Trends At Soulbrain (KOSDAQ:357780) Aren't IdealIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...분석 기사 • Jul 14At ₩288,000, Is Soulbrain Co., Ltd. (KOSDAQ:357780) Worth Looking At Closely?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), is not the largest company out there, but it received a lot of attention from a...분석 기사 • Jun 18Soulbrain (KOSDAQ:357780) Will Want To Turn Around Its Return TrendsWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...분석 기사 • May 02There's Reason For Concern Over Soulbrain Co., Ltd.'s (KOSDAQ:357780) PriceWith a price-to-earnings (or "P/E") ratio of 17.9x Soulbrain Co., Ltd. ( KOSDAQ:357780 ) may be sending bearish signals...분석 기사 • Apr 10Is It Time To Consider Buying Soulbrain Co., Ltd. (KOSDAQ:357780)?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), might not be a large cap stock, but it saw a double-digit share price rise of...Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022)Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.분석 기사 • Mar 20Estimating The Fair Value Of Soulbrain Co., Ltd. (KOSDAQ:357780)Key Insights Soulbrain's estimated fair value is ₩264,305 based on 2 Stage Free Cash Flow to Equity Current share price...분석 기사 • Feb 27Some Investors May Be Worried About Soulbrain's (KOSDAQ:357780) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...Upcoming Dividend • Dec 20Upcoming dividend of ₩2,000 per share at 0.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).Buying Opportunity • Dec 07Now 20% undervaluedOver the last 90 days, the stock is up 31%. The fair value is estimated to be ₩370,680, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 35% in the next 2 years.Major Estimate Revision • Nov 15Consensus EPS estimates increase by 11%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩892.2m to ₩832.2m. EPS estimate rose from ₩16,585 to ₩18,348. Net income forecast to shrink 0.9% next year vs 46% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩307,143. Share price rose 11% to ₩270,500 over the past week.Valuation Update With 7 Day Price Move • Jul 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩275,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩280,170 per share.Reported Earnings • Mar 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea.Major Estimate Revision • Mar 22Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩1.17b to ₩1.05b. EPS estimate fell from ₩22,849 to ₩21,841 per share. Net income forecast to shrink 4.3% next year vs 30% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩291,222. Share price fell 3.9% to ₩210,000 over the past week.Upcoming Dividend • Dec 21Upcoming dividend of ₩1,950 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 8.5% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).공시 • Sep 30Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for KRW 5,000 million worth of its shares.Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust agreement with Mirae Asset Securities Co., Ltd. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until March 29, 2023. As of September 28, 2022, the company had no common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions.Buying Opportunity • Apr 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.9%. The fair value is estimated to be ₩296,525, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last year. Earnings per share has grown by 17%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 34% in the next 2 years.Buying Opportunity • Mar 07Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩276,943, however this is not to be taken as a buy recommendation but rather should be used as a guide only.Upcoming Dividend • Dec 22Upcoming dividend of ₩1,950 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 24% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.4%).Price Target Changed • Dec 08Price target decreased to ₩356,875Down from ₩388,571, the current price target is an average from 8 analysts. New target price is 26% above last closing price of ₩282,500. Stock is up 14% over the past year. The company is forecast to post earnings per share of ₩19,614 for next year compared to ₩16,288 last year.Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩273,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 9.1% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩261,923 per share.Price Target Changed • Nov 19Price target decreased to ₩359,286Down from ₩388,571, the current price target is an average from 7 analysts. New target price is 45% above last closing price of ₩248,100. Stock is up 0.7% over the past year. The company is forecast to post earnings per share of ₩19,824 for next year compared to ₩16,288 last year.Is New 90 Day High Low • Feb 17New 90-day high: ₩313,600The company is up 31% from its price of ₩240,000 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period.Is New 90 Day High Low • Jan 26New 90-day high: ₩300,000The company is up 36% from its price of ₩219,800 on 28 October 2020. The South Korean market is also up 36% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 43% over the same period.Is New 90 Day High Low • Jan 04New 90-day high: ₩291,400The company is up 30% from its price of ₩224,000 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period.Is New 90 Day High Low • Dec 17New 90-day high: ₩273,800The company is up 17% from its price of ₩233,100 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 20% over the same period.Is New 90 Day High Low • Nov 23New 90-day high: ₩255,900The company is up 10.0% from its price of ₩232,000 on 26 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period.매출 및 비용 세부 내역Soulbrain가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이KOSDAQ:A357780 매출, 비용 및 순이익 (KRW Millions)날짜매출순이익일반관리비연구개발비31 Dec 25923,38279,05855,59633,81630 Sep 25895,86067,34655,22033,20730 Jun 25874,66270,96155,33431,12331 Mar 25862,117103,59050,27729,43431 Dec 24863,356118,43749,11126,58230 Sep 24841,876143,18438,20723,92030 Jun 24809,344142,25133,30923,32131 Mar 24811,748130,93931,71722,81131 Dec 23844,029130,36330,98522,84130 Sep 23909,348126,09850,26924,02030 Jun 23998,158144,71360,33324,06231 Mar 231,052,268160,93064,27023,23031 Dec 221,090,867162,79467,77823,95230 Sep 221,095,909178,97958,99822,58230 Jun 221,095,628173,03852,86221,49731 Mar 221,066,326154,28848,41421,36731 Dec 211,023,913148,51743,88820,60531 Dec 20940,135126,53442,54221,748양질의 수익: A357780는 고품질 수익을 보유하고 있습니다.이익 마진 증가: A357780의 현재 순 이익률 (8.6%)은 지난해 (13.7%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: A357780의 수익은 지난 5년 동안 연평균 13.1% 감소했습니다.성장 가속화: A357780은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: A357780은 지난 1년 동안 수익이 감소(-33.2%)하여 Chemicals 업계 평균(-3.4%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: A357780의 자본 수익률(7.6%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YMaterials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:37종가2026/05/21 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Soulbrain Co., Ltd.는 22명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Dong-je WooBofA Global ResearchYonghwan LeeCGS InternationalJosh YangCitigroup Inc19명의 분석가 더 보기
Reported Earnings • Mar 21Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
분석 기사 • Mar 24There May Be Some Bright Spots In Soulbrain's (KOSDAQ:357780) EarningsSoft earnings didn't appear to concern Soulbrain Co., Ltd.'s ( KOSDAQ:357780 ) shareholders over the last week. Our...
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022)Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.
Reported Earnings • Mar 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea.
Buy Or Sell Opportunity • May 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.8% to ₩392,000. The fair value is estimated to be ₩494,529, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 32% per annum over the same time period.
Price Target Changed • May 05Price target increased by 11% to ₩428,846Up from ₩385,833, the current price target is an average from 13 analysts. New target price is 6.5% below last closing price of ₩458,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩20,528 for next year compared to ₩10,285 last year.
Buy Or Sell Opportunity • Apr 30Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.2% to ₩458,000. The fair value is estimated to be ₩573,521, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 5.7% over the last 3 years. Earnings per share has declined by 24%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 32% per annum over the same time period.
Reported Earnings • Mar 21Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: ₩10,285 (down from ₩15,296 in FY 2024). Revenue: ₩923.4b (up 7.0% from FY 2024). Net income: ₩79.1b (down 33% from FY 2024). Profit margin: 8.6% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 22%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩442,000, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 106% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩419,479 per share.
공시 • Mar 11Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026Soulbrain Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 52, geumto-ro, sujeong-gu, gyeonggi-do, seongnam South Korea
Price Target Changed • Mar 02Price target increased by 8.9% to ₩365,571Up from ₩335,667, the current price target is an average from 14 analysts. New target price is 18% below last closing price of ₩445,500. Stock is up 140% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year.
Valuation Update With 7 Day Price Move • Feb 06Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩407,000, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 75% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩490,528 per share.
Declared Dividend • Feb 06Dividend increased to ₩2,350Dividend of ₩2,350 is 2.2% higher than last year. Ex-date: 30th March 2026 Payment date: 1st January 1970 Dividend yield will be 0.6%, which is lower than the industry average of 1.7%. Sustainability & Growth Dividend is covered by earnings (26% earnings payout ratio) but not covered by cash flows (118% cash payout ratio). The dividend has increased by an average of 3.8% per year over the past 5 years and payments have been stable during that time. EPS is expected to grow by 91% over the next 2 years, which should provide support to the dividend and adequate earnings cover.
분석 기사 • Feb 05Soulbrain (KOSDAQ:357780) Will Be Hoping To Turn Its Returns On Capital AroundThere are a few key trends to look for if we want to identify the next multi-bagger. Typically, we'll want to notice a...
공시 • Feb 05Soulbrain Co., Ltd. announces Annual dividendSoulbrain Co., Ltd. announced Annual dividend of KRW 2350.0000 per share, ex-date on March 30, 2026 and record date on March 31, 2026.
Price Target Changed • Feb 02Price target increased by 7.3% to ₩329,333Up from ₩307,063, the current price target is an average from 15 analysts. New target price is 21% below last closing price of ₩419,500. Stock is up 158% over the past year. The company is forecast to post earnings per share of ₩13,194 for next year compared to ₩15,296 last year.
New Risk • Jan 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (7.5% net profit margin).
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₩339,500, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 47% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩623,091 per share.
분석 기사 • Jan 08Market Participants Recognise Soulbrain Co., Ltd.'s (KOSDAQ:357780) EarningsWith a price-to-earnings (or "P/E") ratio of 33.7x Soulbrain Co., Ltd. ( KOSDAQ:357780 ) may be sending very bearish...
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩229,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years.
Major Estimate Revision • Nov 15Consensus EPS estimates increase by 14%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate increased from ₩14,296 to ₩16,301. Revenue forecast steady at ₩922.7m. Net income forecast to grow 92% next year vs 49% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩289,643. Share price rose 3.5% to ₩268,000 over the past week.
분석 기사 • Nov 07What Is Soulbrain Co., Ltd.'s (KOSDAQ:357780) Share Price Doing?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), is not the largest company out there, but it led the KOSDAQ gainers with a...
분석 기사 • Oct 22Soulbrain's (KOSDAQ:357780) Returns On Capital Not Reflecting Well On The BusinessIf we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...
분석 기사 • Sep 19Soulbrain Co., Ltd. (KOSDAQ:357780) Stocks Shoot Up 26% But Its P/E Still Looks ReasonableDespite an already strong run, Soulbrain Co., Ltd. ( KOSDAQ:357780 ) shares have been powering on, with a gain of 26...
Valuation Update With 7 Day Price Move • Sep 12Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩242,000, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 22% over the past three years.
분석 기사 • Sep 07These 4 Measures Indicate That Soulbrain (KOSDAQ:357780) Is Using Debt Reasonably WellWarren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
New Risk • Aug 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Large one-off items impacting financial results.
Major Estimate Revision • Aug 19Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩18,980 to ₩16,480 per share. Revenue forecast steady at ₩938.7m. Net income forecast to grow 35% next year vs 35% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩253,308. Share price fell 2.3% to ₩229,000 over the past week.
Valuation Update With 7 Day Price Move • Jul 30Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩248,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 9.7% over the past three years.
Valuation Update With 7 Day Price Move • Jul 16Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₩211,500, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 3.3% over the past three years.
분석 기사 • Jul 12Soulbrain Co., Ltd.'s (KOSDAQ:357780) P/E Still Appears To Be ReasonableWith a median price-to-earnings (or "P/E") ratio of close to 14x in Korea, you could be forgiven for feeling...
분석 기사 • May 14Is There An Opportunity With Soulbrain Co., Ltd.'s (KOSDAQ:357780) 30% Undervaluation?Key Insights Soulbrain's estimated fair value is ₩265,300 based on 2 Stage Free Cash Flow to Equity Soulbrain's...
공시 • Apr 16Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for 86,009 shares, for KRW 15,000 million.Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to 86,009 shares for KRW 15,000 million worth of its shares pursuant to a trust agreement with NH Investment & Securities Co., Ltd. The shares will be repurchased at a price of KRW 174,400 per share. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until October 14, 2025. As of Aril 14, 2025, the company had 22,994 common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions.
분석 기사 • Apr 15Why Soulbrain Co., Ltd. (KOSDAQ:357780) Could Be Worth WatchingSoulbrain Co., Ltd. ( KOSDAQ:357780 ), might not be a large cap stock, but it saw a double-digit share price rise of...
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₩161,200, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 31% over the past three years.
분석 기사 • Mar 24There May Be Some Bright Spots In Soulbrain's (KOSDAQ:357780) EarningsSoft earnings didn't appear to concern Soulbrain Co., Ltd.'s ( KOSDAQ:357780 ) shareholders over the last week. Our...
Upcoming Dividend • Mar 21Upcoming dividend of ₩2,300 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.0%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (1.7%).
Major Estimate Revision • Mar 19Consensus EPS estimates fall by 11%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from ₩20,044 to ₩17,886 per share. Revenue forecast steady at ₩901.4m. Net income forecast to grow 9.4% next year vs 26% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩257,385. Share price was steady at ₩204,500 over the past week.
공시 • Mar 11Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025Soulbrain Co., Ltd., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 34-12, gongdan-gil, chungcheongnam-do, gongju South Korea
분석 기사 • Feb 21Soulbrain (KOSDAQ:357780) Might Be Having Difficulty Using Its Capital EffectivelyIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Valuation Update With 7 Day Price Move • Feb 10Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩188,100, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 8x in the Chemicals industry in South Korea. Total loss to shareholders of 14% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩331,465 per share.
분석 기사 • Jan 09Is There An Opportunity With Soulbrain Co., Ltd.'s (KOSDAQ:357780) 49% Undervaluation?Key Insights The projected fair value for Soulbrain is ₩351,381 based on 2 Stage Free Cash Flow to Equity Soulbrain is...
Upcoming Dividend • Dec 20Upcoming dividend of ₩2,000 per shareEligible shareholders must have bought the stock before 27 December 2024. Payment date: 21 April 2025. Payout ratio is a comfortable 11% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of South Korean dividend payers (3.9%). Lower than average of industry peers (2.2%).
Board Change • Dec 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
분석 기사 • Dec 02Unpleasant Surprises Could Be In Store For Soulbrain Co., Ltd.'s (KOSDAQ:357780) SharesWith a median price-to-earnings (or "P/E") ratio of close to 11x in Korea, you could be forgiven for feeling...
Price Target Changed • Nov 16Price target decreased by 13% to ₩317,692Down from ₩363,167, the current price target is an average from 13 analysts. New target price is 66% above last closing price of ₩191,300. Stock is down 29% over the past year. The company is forecast to post earnings per share of ₩20,134 for next year compared to ₩16,832 last year.
분석 기사 • Nov 07At ₩204,500, Is Soulbrain Co., Ltd. (KOSDAQ:357780) Worth Looking At Closely?While Soulbrain Co., Ltd. ( KOSDAQ:357780 ) might not have the largest market cap around , it saw significant share...
분석 기사 • Oct 09Capital Allocation Trends At Soulbrain (KOSDAQ:357780) Aren't IdealIf you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...
분석 기사 • Jul 14At ₩288,000, Is Soulbrain Co., Ltd. (KOSDAQ:357780) Worth Looking At Closely?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), is not the largest company out there, but it received a lot of attention from a...
분석 기사 • Jun 18Soulbrain (KOSDAQ:357780) Will Want To Turn Around Its Return TrendsWhat trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...
분석 기사 • May 02There's Reason For Concern Over Soulbrain Co., Ltd.'s (KOSDAQ:357780) PriceWith a price-to-earnings (or "P/E") ratio of 17.9x Soulbrain Co., Ltd. ( KOSDAQ:357780 ) may be sending bearish signals...
분석 기사 • Apr 10Is It Time To Consider Buying Soulbrain Co., Ltd. (KOSDAQ:357780)?Soulbrain Co., Ltd. ( KOSDAQ:357780 ), might not be a large cap stock, but it saw a double-digit share price rise of...
Reported Earnings • Mar 22Full year 2023 earnings released: EPS: ₩16,832 (vs ₩20,967 in FY 2022)Full year 2023 results: EPS: ₩16,832 (down from ₩20,967 in FY 2022). Revenue: ₩844.0b (down 23% from FY 2022). Net income: ₩130.4b (down 20% from FY 2022). Profit margin: 15% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.
분석 기사 • Mar 20Estimating The Fair Value Of Soulbrain Co., Ltd. (KOSDAQ:357780)Key Insights Soulbrain's estimated fair value is ₩264,305 based on 2 Stage Free Cash Flow to Equity Current share price...
분석 기사 • Feb 27Some Investors May Be Worried About Soulbrain's (KOSDAQ:357780) Returns On CapitalIf you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...
Upcoming Dividend • Dec 20Upcoming dividend of ₩2,000 per share at 0.7% yieldEligible shareholders must have bought the stock before 27 December 2023. Payment date: 22 April 2024. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%).
Buying Opportunity • Dec 07Now 20% undervaluedOver the last 90 days, the stock is up 31%. The fair value is estimated to be ₩370,680, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 35% in the next 2 years.
Major Estimate Revision • Nov 15Consensus EPS estimates increase by 11%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩892.2m to ₩832.2m. EPS estimate rose from ₩16,585 to ₩18,348. Net income forecast to shrink 0.9% next year vs 46% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩307,143. Share price rose 11% to ₩270,500 over the past week.
Valuation Update With 7 Day Price Move • Jul 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩275,500, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 24% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩280,170 per share.
Reported Earnings • Mar 26Full year 2022 earnings: EPS and revenues miss analyst expectationsFull year 2022 results: EPS: ₩20,967 (up from ₩19,124 in FY 2021). Revenue: ₩1.09t (up 6.5% from FY 2021). Net income: ₩162.8b (up 9.6% from FY 2021). Profit margin: 15% (in line with FY 2021). Revenue missed analyst estimates by 1.9%. Earnings per share (EPS) also missed analyst estimates by 11%. Revenue is forecast to grow 6.4% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in South Korea.
Major Estimate Revision • Mar 22Consensus revenue estimates fall by 10%The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩1.17b to ₩1.05b. EPS estimate fell from ₩22,849 to ₩21,841 per share. Net income forecast to shrink 4.3% next year vs 30% growth forecast for Chemicals industry in South Korea . Consensus price target broadly unchanged at ₩291,222. Share price fell 3.9% to ₩210,000 over the past week.
Upcoming Dividend • Dec 21Upcoming dividend of ₩1,950 per shareEligible shareholders must have bought the stock before 28 December 2022. Payment date: 17 April 2023. Payout ratio is a comfortable 8.5% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%).
공시 • Sep 30Soulbrain Co., Ltd. (KOSDAQ:A357780) announces an Equity Buyback for KRW 5,000 million worth of its shares.Soulbrain Co., Ltd. (KOSDAQ:A357780) announces a share repurchase program. Under the program, the company will repurchase up to KRW 5,000 million worth of its shares pursuant to a trust agreement with Mirae Asset Securities Co., Ltd. The purpose behind the program is to stabilize the stock price and to enhance shareholder value. The program will continue until March 29, 2023. As of September 28, 2022, the company had no common shares within dividend capacity and had 12,430 shares in treasury through other acquisitions.
Buying Opportunity • Apr 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 9.9%. The fair value is estimated to be ₩296,525, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last year. Earnings per share has grown by 17%. Revenue is forecast to grow by 28% in 2 years. Earnings is forecast to grow by 34% in the next 2 years.
Buying Opportunity • Mar 07Now 23% undervalued after recent price dropOver the last 90 days, the stock is down 24%. The fair value is estimated to be ₩276,943, however this is not to be taken as a buy recommendation but rather should be used as a guide only.
Upcoming Dividend • Dec 22Upcoming dividend of ₩1,950 per shareEligible shareholders must have bought the stock before 29 December 2021. Payment date: 18 April 2022. Payout ratio is a comfortable 24% but the company is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.4%).
Price Target Changed • Dec 08Price target decreased to ₩356,875Down from ₩388,571, the current price target is an average from 8 analysts. New target price is 26% above last closing price of ₩282,500. Stock is up 14% over the past year. The company is forecast to post earnings per share of ₩19,614 for next year compared to ₩16,288 last year.
Valuation Update With 7 Day Price Move • Nov 24Investor sentiment improved over the past weekAfter last week's 17% share price gain to ₩273,800, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 9.1% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩261,923 per share.
Price Target Changed • Nov 19Price target decreased to ₩359,286Down from ₩388,571, the current price target is an average from 7 analysts. New target price is 45% above last closing price of ₩248,100. Stock is up 0.7% over the past year. The company is forecast to post earnings per share of ₩19,824 for next year compared to ₩16,288 last year.
Is New 90 Day High Low • Feb 17New 90-day high: ₩313,600The company is up 31% from its price of ₩240,000 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 29% over the same period.
Is New 90 Day High Low • Jan 26New 90-day high: ₩300,000The company is up 36% from its price of ₩219,800 on 28 October 2020. The South Korean market is also up 36% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Chemicals industry, which is up 43% over the same period.
Is New 90 Day High Low • Jan 04New 90-day high: ₩291,400The company is up 30% from its price of ₩224,000 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 22% over the same period.
Is New 90 Day High Low • Dec 17New 90-day high: ₩273,800The company is up 17% from its price of ₩233,100 on 18 September 2020. The South Korean market is up 14% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 20% over the same period.
Is New 90 Day High Low • Nov 23New 90-day high: ₩255,900The company is up 10.0% from its price of ₩232,000 on 26 August 2020. The South Korean market is up 9.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Chemicals industry, which is up 13% over the same period.